Astragaloside IV potentiates cisplatin sensitivity in triple-negative breast cancer via STING signaling pathway activation

As synergistically enhances the therapeutic efficacy of cisplatin against TNBC while ameliorating its adverse effects, primarily through activation of the STING signaling pathway and potentiation of antitumor immunity. This dual mechanism-simultaneously boosting host defense ("Fuzheng") and inhibiting tumor progression ("Kang`ai")-provides a molecular basis for the observed "Qi-tonifying" properties of As in traditional Chinese medicine (TCM), bridging TCM with contemporary immunopharmacology.